Pancreatic Cancer - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：956頁
文件格式：PDF
價 格：
USD 2,500 (Single-User License)
USD 5,000 (Multi-User License)
USD 7,500 (Global-User License)
USD 5,000 (Multi-User License)
USD 7,500 (Global-User License)
Pancreatic Cancer - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Pancreatic Cancer - Pipeline Review, H1 2014’, provides an overview of the Pancreatic Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pancreatic Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Pancreatic Cancer - Pipeline Review, H1 2014’, provides an overview of the Pancreatic Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pancreatic Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 10
Pancreatic Cancer Overview 11
Therapeutics Development 12
Pancreatic Cancer - Therapeutics under Development by Companies 14
Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 30
Pancreatic Cancer - Pipeline Products Glance 35
Pancreatic Cancer - Products under Development by Companies 39
Pancreatic Cancer - Products under Investigation by Universities/Institutes 56
Pancreatic Cancer - Companies Involved in Therapeutics Development 60
Pancreatic Cancer - Therapeutics Assessment 235
Drug Profiles 265
Pancreatic Cancer - Recent Pipeline Updates 720
Pancreatic Cancer - Dormant Projects 900
Pancreatic Cancer - Discontinued Products 912
Pancreatic Cancer - Product Development Milestones 913
Appendix 921
List of Tables
Number of Products under Development for Pancreatic Cancer, H1 2014 46
Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H1 2014 47
Number of Products under Development by Companies, H1 2014 49
Number of Products under Development by Companies, H1 2014 (Contd..1) 50
Number of Products under Development by Companies, H1 2014 (Contd..2) 51
Number of Products under Development by Companies, H1 2014 (Contd..3) 52
Number of Products under Development by Companies, H1 2014 (Contd..4) 53
Number of Products under Development by Companies, H1 2014 (Contd..5) 54
Number of Products under Development by Companies, H1 2014 (Contd..6) 55
Number of Products under Development by Companies, H1 2014 (Contd..7) 56
Number of Products under Development by Companies, H1 2014 (Contd..8) 57
Number of Products under Development by Companies, H1 2014 (Contd..9) 58
Number of Products under Development by Companies, H1 2014 (Contd..10) 59
Number of Products under Development by Companies, H1 2014 (Contd..11) 60
Number of Products under Development by Companies, H1 2014 (Contd..12) 61
Number of Products under Development by Companies, H1 2014 (Contd..13) 62
Number of Products under Development by Companies, H1 2014 (Contd..14) 63
Number of Products under Investigation by Universities/Institutes, H1 2014 65
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 66
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 67
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 68
Comparative Analysis by Late Stage Development, H1 2014 69
Comparative Analysis by Clinical Stage Development, H1 2014 70
Comparative Analysis by Early Stage Development, H1 2014 71
Comparative Analysis by Unknown Stage Development, H1 2014 72
Products under Development by Companies, H1 2014 73
Products under Development by Companies, H1 2014 (Contd..1) 74
Products under Development by Companies, H1 2014 (Contd..2) 75
Products under Development by Companies, H1 2014 (Contd..3) 76
Products under Development by Companies, H1 2014 (Contd..4) 77
Products under Development by Companies, H1 2014 (Contd..5) 78
Products under Development by Companies, H1 2014 (Contd..6) 79
Products under Development by Companies, H1 2014 (Contd..7) 80
Products under Development by Companies, H1 2014 (Contd..8) 81
Products under Development by Companies, H1 2014 (Contd..9) 82
Products under Development by Companies, H1 2014 (Contd..10) 83
Products under Development by Companies, H1 2014 (Contd..11) 84
Products under Development by Companies, H1 2014 (Contd..12) 85
Products under Development by Companies, H1 2014 (Contd..13) 86
Products under Development by Companies, H1 2014 (Contd..14) 87
Products under Development by Companies, H1 2014 (Contd..15) 88
Products under Development by Companies, H1 2014 (Contd..16) 89
Products under Investigation by Universities/Institutes, H1 2014 90
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 91
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 92
Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 93
Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2014 94
Pancreatic Cancer - Pipeline by Celsion Corporation, H1 2014 95
Pancreatic Cancer - Pipeline by Sanofi, H1 2014 96
Pancreatic Cancer - Pipeline by Eli Lilly and Company, H1 2014 97
Pancreatic Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 98
Pancreatic Cancer - Pipeline by Genentech, Inc., H1 2014 99
Pancreatic Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 100
Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H1 2014 101
Pancreatic Cancer - Pipeline by Biotest AG, H1 2014 102
Pancreatic Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 103
Pancreatic Cancer - Pipeline by Merck & Co., Inc., H1 2014 104
Pancreatic Cancer - Pipeline by AbGenomics International, Inc., H1 2014 105
Pancreatic Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 106
Pancreatic Cancer - Pipeline by Symphogen A/S, H1 2014 107
Pancreatic Cancer - Pipeline by Piramal Enterprises Limited, H1 2014 108
Pancreatic Cancer - Pipeline by Aposense Ltd., H1 2014 109
Pancreatic Cancer - Pipeline by ZIOPHARM Oncology, Inc., H1 2014 110
Pancreatic Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 111
Pancreatic Cancer - Pipeline by Novartis AG, H1 2014 112
Pancreatic Cancer - Pipeline by Samyang Holdings Corporation, H1 2014 113
Pancreatic Cancer - Pipeline by Aphios Corporation, H1 2014 114
Pancreatic Cancer - Pipeline by CK Life Sciences Int'l., (Holdings) Inc., H1 2014 115
Pancreatic Cancer - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2014 116
Pancreatic Cancer - Pipeline by Ono Pharmaceutical Co. Ltd., H1 2014 117
Pancreatic Cancer - Pipeline by Pfizer Inc., H1 2014 118
Pancreatic Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 119
Pancreatic Cancer - Pipeline by Takara Holdings Inc., H1 2014 120
Pancreatic Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 121
Pancreatic Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2014 122
Pancreatic Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H1 2014 123
Pancreatic Cancer - Pipeline by Genmab A/S, H1 2014 124
Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H1 2014 125
Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals Inc., H1 2014 126
Pancreatic Cancer - Pipeline by Celgene Corporation, H1 2014 127
Pancreatic Cancer - Pipeline by Bayer AG, H1 2014 128
Pancreatic Cancer - Pipeline by Incyte Corporation, H1 2014 129
Pancreatic Cancer - Pipeline by Merck KGaA, H1 2014 130
Pancreatic Cancer - Pipeline by Advaxis, Inc., H1 2014 131
Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp., H1 2014 132
Pancreatic Cancer - Pipeline by ValiRx Plc, H1 2014 133
Pancreatic Cancer - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2014 134
Pancreatic Cancer - Pipeline by Immunomedics, Inc., H1 2014 135
Pancreatic Cancer - Pipeline by Genfit SA, H1 2014 136
Pancreatic Cancer - Pipeline by Lorus Therapeutics Inc., H1 2014 137
Pancreatic Cancer - Pipeline by Bionomics Limited, H1 2014 138
Pancreatic Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2014 139
Pancreatic Cancer - Pipeline by Patrys Limited, H1 2014 140
Pancreatic Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2014 141
Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2014 142
Pancreatic Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2014 143
Pancreatic Cancer - Pipeline by Pharmacyclics, Inc., H1 2014 144
Pancreatic Cancer - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 145
Pancreatic Cancer - Pipeline by CrystalGenomics, Inc., H1 2014 146
Pancreatic Cancer - Pipeline by Natco Pharma Limited, H1 2014 147
Pancreatic Cancer - Pipeline by Sareum Holdings plc, H1 2014 148
Pancreatic Cancer - Pipeline by Microbio Co., Ltd., H1 2014 149
Pancreatic Cancer - Pipeline by DiaMedica Inc., H1 2014 150
Pancreatic Cancer - Pipeline by Oscotec Inc., H1 2014 151
Pancreatic Cancer - Pipeline by MabVax Therapeutics, Inc., H1 2014 152
Pancreatic Cancer - Pipeline by Nanobiotix SA, H1 2014 153
Pancreatic Cancer - Pipeline by Morphotek, Inc., H1 2014 154
Pancreatic Cancer - Pipeline by Isarna Therapeutics GmbH, H1 2014 155
Pancreatic Cancer - Pipeline by Wilex AG, H1 2014 156
Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Limited, H1 2014 157
Pancreatic Cancer - Pipeline by Meabco A/S, H1 2014 158
Pancreatic Cancer - Pipeline by Ganymed Pharmaceuticals AG, H1 2014 159
Pancreatic Cancer - Pipeline by Philogen S.p.A., H1 2014 160
Pancreatic Cancer - Pipeline by Quantum Pharmaceuticals, H1 2014 161
Pancreatic Cancer - Pipeline by Multimmune GmbH, H1 2014 162
Pancreatic Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H1 2014 163
Pancreatic Cancer - Pipeline by Hutchison MediPharma Limited, H1 2014 164
Pancreatic Cancer - Pipeline by Erytech Pharma SA, H1 2014 165
Pancreatic Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2014 166
Pancreatic Cancer - Pipeline by Cellectis S.A., H1 2014 167
Pancreatic Cancer - Pipeline by Ascenta Therapeutics, Inc., H1 2014 168
Pancreatic Cancer - Pipeline by Phoenix Biotechnology, Inc., H1 2014 169
Pancreatic Cancer - Pipeline by Heat Biologics, Inc., H1 2014 170
Pancreatic Cancer - Pipeline by Antyra, Inc., H1 2014 171
Pancreatic Cancer - Pipeline by Ambrx, Inc., H1 2014 172
Pancreatic Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2014 173
Pancreatic Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2014 174
Pancreatic Cancer - Pipeline by Kalos Therapeutics, Inc., H1 2014 175
Pancreatic Cancer - Pipeline by Azaya Therapeutics Incorporated, H1 2014 176
Pancreatic Cancer - Pipeline by Innopharmax Inc., H1 2014 177
Pancreatic Cancer - Pipeline by MSM Protein Technologies, Inc., H1 2014 178
Pancreatic Cancer - Pipeline by Jennerex Biotherapeutics, Inc., H1 2014 179
Pancreatic Cancer - Pipeline by Stemline Therapeutics, Inc., H1 2014 180
Pancreatic Cancer - Pipeline by BioCancell Therapeutics, Inc., H1 2014 181
Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2014 182
Pancreatic Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2014 183
Pancreatic Cancer - Pipeline by Pharminox Limited, H1 2014 184
Pancreatic Cancer - Pipeline by Virobay Inc., H1 2014 185
Pancreatic Cancer - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2014 186
Pancreatic Cancer - Pipeline by Immunotope, Inc., H1 2014 187
Pancreatic Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2014 188
Pancreatic Cancer - Pipeline by Omeros Corporation, H1 2014 189
Pancreatic Cancer - Pipeline by TransTech Pharma, Inc., H1 2014 190
Pancreatic Cancer - Pipeline by Welichem Biotech Inc., H1 2014 191
Pancreatic Cancer - Pipeline by Globeimmune, Inc., H1 2014 192
Pancreatic Cancer - Pipeline by NewLink Genetics Corporation, H1 2014 193
Pancreatic Cancer - Pipeline by Pharma Mar, S.A., H1 2014 194
Pancreatic Cancer - Pipeline by Quintessence Biosciences, Inc., H1 2014 195
Pancreatic Cancer - Pipeline by AB Science, H1 2014 196
Pancreatic Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H1 2014 197
Pancreatic Cancer - Pipeline by CureTech Ltd., H1 2014 198
Pancreatic Cancer - Pipeline by Genelux Corporation, H1 2014 199
Pancreatic Cancer - Pipeline by GlycoMimetics, Inc., H1 2014 200
Pancreatic Cancer - Pipeline by Biothera, Inc., H1 2014 201
Pancreatic Cancer - Pipeline by Medisyn Technologies, Inc., H1 2014 202
Pancreatic Cancer - Pipeline by Keystone Nano, Inc., H1 2014 203
Pancreatic Cancer - Pipeline by Pique Therapeutics, H1 2014 204
Pancreatic Cancer - Pipeline by Arch Biopartners, Inc., H1 2014 205
Pancreatic Cancer - Pipeline by Clovis Oncology, Inc., H1 2014 206
Pancreatic Cancer - Pipeline by 3-V Biosciences, Inc., H1 2014 207
Pancreatic Cancer - Pipeline by PharmAbcine, Inc., H1 2014 208
Pancreatic Cancer - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2014 209
Pancreatic Cancer - Pipeline by Sunshine Biopharma, Inc., H1 2014 210
Pancreatic Cancer - Pipeline by NuCana BioMed Limited, H1 2014 211
Pancreatic Cancer - Pipeline by KAEL-GemVax Co., Ltd., H1 2014 212
Pancreatic Cancer - Pipeline by Nuvilex, Inc., H1 2014 213
Pancreatic Cancer - Pipeline by iCeutica, Inc., H1 2014 214
Pancreatic Cancer - Pipeline by Incuron, LLC, H1 2014 215
Pancreatic Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 216
Pancreatic Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2014 217
Pancreatic Cancer - Pipeline by Polaris Group, H1 2014 218
Pancreatic Cancer - Pipeline by BiOrion Technologies B.V., H1 2014 219
Pancreatic Cancer - Pipeline by DEKK-TEC, Inc., H1 2014 220
Pancreatic Cancer - Pipeline by IkerChem S.L., H1 2014 221
Pancreatic Cancer - Pipeline by Regulon Inc., H1 2014 222
Pancreatic Cancer - Pipeline by TAU Therapeutics, LLC, H1 2014 223
Pancreatic Cancer - Pipeline by Gradalis Inc., H1 2014 224
Pancreatic Cancer - Pipeline by CytoVac A/S, H1 2014 225
Pancreatic Cancer - Pipeline by SignPath Pharma Inc, H1 2014 226
Pancreatic Cancer - Pipeline by BerGenBio AS, H1 2014 227
Pancreatic Cancer - Pipeline by CytomX Therapeutics, Inc., H1 2014 228
Pancreatic Cancer - Pipeline by Intezyne, Inc, H1 2014 229
Pancreatic Cancer - Pipeline by Sialix, Inc., H1 2014 230
Pancreatic Cancer - Pipeline by Igenica, Inc., H1 2014 231
Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals, LLC., H1 2014 232
Pancreatic Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 233
Pancreatic Cancer - Pipeline by Apexigen, Inc., H1 2014 234
Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H1 2014 235
Pancreatic Cancer - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014 236
Pancreatic Cancer - Pipeline by centrose llc, H1 2014 237
Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd., H1 2014 238
Pancreatic Cancer - Pipeline by NeoPharm Co., Ltd., H1 2014 239
Pancreatic Cancer - Pipeline by CureFAKtor Pharmaceuticals. LLC, H1 2014 240
Pancreatic Cancer - Pipeline by Kancera AB, H1 2014 241
Pancreatic Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H1 2014 242
Pancreatic Cancer - Pipeline by Vaxeal Holding SA, H1 2014 243
Pancreatic Cancer - Pipeline by Pharma Two B Ltd, H1 2014 244
Pancreatic Cancer - Pipeline by Valens Therapeutics, Inc., H1 2014 245
Pancreatic Cancer - Pipeline by Qu Biologics Inc., H1 2014 246
Pancreatic Cancer - Pipeline by CZ BioMed Corp, H1 2014 247
Pancreatic Cancer - Pipeline by IMPACT Therapeutics, Inc., H1 2014 248
Pancreatic Cancer - Pipeline by LivTech, Inc., H1 2014 249
Pancreatic Cancer - Pipeline by Io Therapeutics, Inc., H1 2014 250
Pancreatic Cancer - Pipeline by Bioncotech Therapeutics S.L., H1 2014 251
Pancreatic Cancer - Pipeline by Tactic Pharma, LLC, H1 2014 252
Pancreatic Cancer - Pipeline by Immune Pharmaceuticals, Inc., H1 2014 253
Pancreatic Cancer - Pipeline by Targovax AS, H1 2014 254
Pancreatic Cancer - Pipeline by InvivoGen Therapeutics, H1 2014 255
Pancreatic Cancer - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 256
Pancreatic Cancer - Pipeline by StemPar Sciences, Inc., H1 2014 257
Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H1 2014 258
Pancreatic Cancer - Pipeline by Oncomatrix, S.L., H1 2014 259
Pancreatic Cancer - Pipeline by Argon Pharma S.L., H1 2014 260
Pancreatic Cancer - Pipeline by cCAM Biotherapeutics Ltd., H1 2014 261
Pancreatic Cancer - Pipeline by Ability Pharma, SL, H1 2014 262
Pancreatic Cancer - Pipeline by Pharmedartis GmbH, H1 2014 263
Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H1 2014 264
Pancreatic Cancer - Pipeline by Oncology Research International Limited, H1 2014 265
Pancreatic Cancer - Pipeline by MediaPharma s.r.l., H1 2014 266
Pancreatic Cancer - Pipeline by TARGETOME, H1 2014 267
Pancreatic Cancer - Pipeline by Huabo Biopharm Co., Ltd., H1 2014 268
Assessment by Monotherapy Products, H1 2014 269
Assessment by Combination Products, H1 2014 270
Number of Products by Stage and Target, H1 2014 273
Number of Products by Stage and Mechanism of Action, H1 2014 284
Number of Products by Stage and Route of Administration, H1 2014 295
Number of Products by Stage and Molecule Type, H1 2014 298
Pancreatic Cancer Therapeutics - Recent Pipeline Updates, H1 2014 754
Pancreatic Cancer - Dormant Projects, H1 2014 934
Pancreatic Cancer - Dormant Projects (Contd..1), H1 2014 935
Pancreatic Cancer - Dormant Projects (Contd..2), H1 2014 936
Pancreatic Cancer - Dormant Projects (Contd..3), H1 2014 937
Pancreatic Cancer - Dormant Projects (Contd..4), H1 2014 938
Pancreatic Cancer - Dormant Projects (Contd..5), H1 2014 939
Pancreatic Cancer - Dormant Projects (Contd..6), H1 2014 940
Pancreatic Cancer - Dormant Projects (Contd..7), H1 2014 941
Pancreatic Cancer - Dormant Projects (Contd..8), H1 2014 942
Pancreatic Cancer - Dormant Projects (Contd..9), H1 2014 943
Pancreatic Cancer - Dormant Projects (Contd..10), H1 2014 944
Pancreatic Cancer - Dormant Projects (Contd..11), H1 2014 945
Pancreatic Cancer - Discontinued Products, H1 2014 946
List of Figures
Number of Products under Development for Pancreatic Cancer, H1 2014 46
Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H1 2014 47
Number of Products under Development by Companies, H1 2014 48
Number of Products under Investigation by Universities/Institutes, H1 2014 64
Comparative Analysis by Clinical Stage Development, H1 2014 69
Comparative Analysis by Clinical Stage Development, H1 2014 70
Comparative Analysis by Early Stage Products, H1 2014 71
Assessment by Monotherapy Products, H1 2014 269
Assessment by Combination Products, H1 2014 270
Number of Products by Top 10 Target, H1 2014 271
Number of Products by Stage and Top 10 Target, H1 2014 272
Number of Products by Top 10 Mechanism of Action, H1 2014 282
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 283
Number of Products by Top 10 Route of Administration, H1 2014 293
Number of Products by Stage and Top 10 Route of Administration, H1 2014 294
Number of Products by Top 10 Molecule Type, H1 2014 296
Number of Products by Stage and Top 10 Molecule Type, H1 2014 297
Table of Contents 2
Introduction 10
Pancreatic Cancer Overview 11
Therapeutics Development 12
Pancreatic Cancer - Therapeutics under Development by Companies 14
Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 30
Pancreatic Cancer - Pipeline Products Glance 35
Pancreatic Cancer - Products under Development by Companies 39
Pancreatic Cancer - Products under Investigation by Universities/Institutes 56
Pancreatic Cancer - Companies Involved in Therapeutics Development 60
Pancreatic Cancer - Therapeutics Assessment 235
Drug Profiles 265
Pancreatic Cancer - Recent Pipeline Updates 720
Pancreatic Cancer - Dormant Projects 900
Pancreatic Cancer - Discontinued Products 912
Pancreatic Cancer - Product Development Milestones 913
Appendix 921
List of Tables
Number of Products under Development for Pancreatic Cancer, H1 2014 46
Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H1 2014 47
Number of Products under Development by Companies, H1 2014 49
Number of Products under Development by Companies, H1 2014 (Contd..1) 50
Number of Products under Development by Companies, H1 2014 (Contd..2) 51
Number of Products under Development by Companies, H1 2014 (Contd..3) 52
Number of Products under Development by Companies, H1 2014 (Contd..4) 53
Number of Products under Development by Companies, H1 2014 (Contd..5) 54
Number of Products under Development by Companies, H1 2014 (Contd..6) 55
Number of Products under Development by Companies, H1 2014 (Contd..7) 56
Number of Products under Development by Companies, H1 2014 (Contd..8) 57
Number of Products under Development by Companies, H1 2014 (Contd..9) 58
Number of Products under Development by Companies, H1 2014 (Contd..10) 59
Number of Products under Development by Companies, H1 2014 (Contd..11) 60
Number of Products under Development by Companies, H1 2014 (Contd..12) 61
Number of Products under Development by Companies, H1 2014 (Contd..13) 62
Number of Products under Development by Companies, H1 2014 (Contd..14) 63
Number of Products under Investigation by Universities/Institutes, H1 2014 65
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 66
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 67
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 68
Comparative Analysis by Late Stage Development, H1 2014 69
Comparative Analysis by Clinical Stage Development, H1 2014 70
Comparative Analysis by Early Stage Development, H1 2014 71
Comparative Analysis by Unknown Stage Development, H1 2014 72
Products under Development by Companies, H1 2014 73
Products under Development by Companies, H1 2014 (Contd..1) 74
Products under Development by Companies, H1 2014 (Contd..2) 75
Products under Development by Companies, H1 2014 (Contd..3) 76
Products under Development by Companies, H1 2014 (Contd..4) 77
Products under Development by Companies, H1 2014 (Contd..5) 78
Products under Development by Companies, H1 2014 (Contd..6) 79
Products under Development by Companies, H1 2014 (Contd..7) 80
Products under Development by Companies, H1 2014 (Contd..8) 81
Products under Development by Companies, H1 2014 (Contd..9) 82
Products under Development by Companies, H1 2014 (Contd..10) 83
Products under Development by Companies, H1 2014 (Contd..11) 84
Products under Development by Companies, H1 2014 (Contd..12) 85
Products under Development by Companies, H1 2014 (Contd..13) 86
Products under Development by Companies, H1 2014 (Contd..14) 87
Products under Development by Companies, H1 2014 (Contd..15) 88
Products under Development by Companies, H1 2014 (Contd..16) 89
Products under Investigation by Universities/Institutes, H1 2014 90
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 91
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 92
Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 93
Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2014 94
Pancreatic Cancer - Pipeline by Celsion Corporation, H1 2014 95
Pancreatic Cancer - Pipeline by Sanofi, H1 2014 96
Pancreatic Cancer - Pipeline by Eli Lilly and Company, H1 2014 97
Pancreatic Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 98
Pancreatic Cancer - Pipeline by Genentech, Inc., H1 2014 99
Pancreatic Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 100
Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H1 2014 101
Pancreatic Cancer - Pipeline by Biotest AG, H1 2014 102
Pancreatic Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 103
Pancreatic Cancer - Pipeline by Merck & Co., Inc., H1 2014 104
Pancreatic Cancer - Pipeline by AbGenomics International, Inc., H1 2014 105
Pancreatic Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 106
Pancreatic Cancer - Pipeline by Symphogen A/S, H1 2014 107
Pancreatic Cancer - Pipeline by Piramal Enterprises Limited, H1 2014 108
Pancreatic Cancer - Pipeline by Aposense Ltd., H1 2014 109
Pancreatic Cancer - Pipeline by ZIOPHARM Oncology, Inc., H1 2014 110
Pancreatic Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 111
Pancreatic Cancer - Pipeline by Novartis AG, H1 2014 112
Pancreatic Cancer - Pipeline by Samyang Holdings Corporation, H1 2014 113
Pancreatic Cancer - Pipeline by Aphios Corporation, H1 2014 114
Pancreatic Cancer - Pipeline by CK Life Sciences Int'l., (Holdings) Inc., H1 2014 115
Pancreatic Cancer - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2014 116
Pancreatic Cancer - Pipeline by Ono Pharmaceutical Co. Ltd., H1 2014 117
Pancreatic Cancer - Pipeline by Pfizer Inc., H1 2014 118
Pancreatic Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 119
Pancreatic Cancer - Pipeline by Takara Holdings Inc., H1 2014 120
Pancreatic Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 121
Pancreatic Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2014 122
Pancreatic Cancer - Pipeline by Zeria Pharmaceutical Co Ltd, H1 2014 123
Pancreatic Cancer - Pipeline by Genmab A/S, H1 2014 124
Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H1 2014 125
Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals Inc., H1 2014 126
Pancreatic Cancer - Pipeline by Celgene Corporation, H1 2014 127
Pancreatic Cancer - Pipeline by Bayer AG, H1 2014 128
Pancreatic Cancer - Pipeline by Incyte Corporation, H1 2014 129
Pancreatic Cancer - Pipeline by Merck KGaA, H1 2014 130
Pancreatic Cancer - Pipeline by Advaxis, Inc., H1 2014 131
Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp., H1 2014 132
Pancreatic Cancer - Pipeline by ValiRx Plc, H1 2014 133
Pancreatic Cancer - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2014 134
Pancreatic Cancer - Pipeline by Immunomedics, Inc., H1 2014 135
Pancreatic Cancer - Pipeline by Genfit SA, H1 2014 136
Pancreatic Cancer - Pipeline by Lorus Therapeutics Inc., H1 2014 137
Pancreatic Cancer - Pipeline by Bionomics Limited, H1 2014 138
Pancreatic Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2014 139
Pancreatic Cancer - Pipeline by Patrys Limited, H1 2014 140
Pancreatic Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2014 141
Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2014 142
Pancreatic Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2014 143
Pancreatic Cancer - Pipeline by Pharmacyclics, Inc., H1 2014 144
Pancreatic Cancer - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 145
Pancreatic Cancer - Pipeline by CrystalGenomics, Inc., H1 2014 146
Pancreatic Cancer - Pipeline by Natco Pharma Limited, H1 2014 147
Pancreatic Cancer - Pipeline by Sareum Holdings plc, H1 2014 148
Pancreatic Cancer - Pipeline by Microbio Co., Ltd., H1 2014 149
Pancreatic Cancer - Pipeline by DiaMedica Inc., H1 2014 150
Pancreatic Cancer - Pipeline by Oscotec Inc., H1 2014 151
Pancreatic Cancer - Pipeline by MabVax Therapeutics, Inc., H1 2014 152
Pancreatic Cancer - Pipeline by Nanobiotix SA, H1 2014 153
Pancreatic Cancer - Pipeline by Morphotek, Inc., H1 2014 154
Pancreatic Cancer - Pipeline by Isarna Therapeutics GmbH, H1 2014 155
Pancreatic Cancer - Pipeline by Wilex AG, H1 2014 156
Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Limited, H1 2014 157
Pancreatic Cancer - Pipeline by Meabco A/S, H1 2014 158
Pancreatic Cancer - Pipeline by Ganymed Pharmaceuticals AG, H1 2014 159
Pancreatic Cancer - Pipeline by Philogen S.p.A., H1 2014 160
Pancreatic Cancer - Pipeline by Quantum Pharmaceuticals, H1 2014 161
Pancreatic Cancer - Pipeline by Multimmune GmbH, H1 2014 162
Pancreatic Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H1 2014 163
Pancreatic Cancer - Pipeline by Hutchison MediPharma Limited, H1 2014 164
Pancreatic Cancer - Pipeline by Erytech Pharma SA, H1 2014 165
Pancreatic Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2014 166
Pancreatic Cancer - Pipeline by Cellectis S.A., H1 2014 167
Pancreatic Cancer - Pipeline by Ascenta Therapeutics, Inc., H1 2014 168
Pancreatic Cancer - Pipeline by Phoenix Biotechnology, Inc., H1 2014 169
Pancreatic Cancer - Pipeline by Heat Biologics, Inc., H1 2014 170
Pancreatic Cancer - Pipeline by Antyra, Inc., H1 2014 171
Pancreatic Cancer - Pipeline by Ambrx, Inc., H1 2014 172
Pancreatic Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2014 173
Pancreatic Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2014 174
Pancreatic Cancer - Pipeline by Kalos Therapeutics, Inc., H1 2014 175
Pancreatic Cancer - Pipeline by Azaya Therapeutics Incorporated, H1 2014 176
Pancreatic Cancer - Pipeline by Innopharmax Inc., H1 2014 177
Pancreatic Cancer - Pipeline by MSM Protein Technologies, Inc., H1 2014 178
Pancreatic Cancer - Pipeline by Jennerex Biotherapeutics, Inc., H1 2014 179
Pancreatic Cancer - Pipeline by Stemline Therapeutics, Inc., H1 2014 180
Pancreatic Cancer - Pipeline by BioCancell Therapeutics, Inc., H1 2014 181
Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2014 182
Pancreatic Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2014 183
Pancreatic Cancer - Pipeline by Pharminox Limited, H1 2014 184
Pancreatic Cancer - Pipeline by Virobay Inc., H1 2014 185
Pancreatic Cancer - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2014 186
Pancreatic Cancer - Pipeline by Immunotope, Inc., H1 2014 187
Pancreatic Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2014 188
Pancreatic Cancer - Pipeline by Omeros Corporation, H1 2014 189
Pancreatic Cancer - Pipeline by TransTech Pharma, Inc., H1 2014 190
Pancreatic Cancer - Pipeline by Welichem Biotech Inc., H1 2014 191
Pancreatic Cancer - Pipeline by Globeimmune, Inc., H1 2014 192
Pancreatic Cancer - Pipeline by NewLink Genetics Corporation, H1 2014 193
Pancreatic Cancer - Pipeline by Pharma Mar, S.A., H1 2014 194
Pancreatic Cancer - Pipeline by Quintessence Biosciences, Inc., H1 2014 195
Pancreatic Cancer - Pipeline by AB Science, H1 2014 196
Pancreatic Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H1 2014 197
Pancreatic Cancer - Pipeline by CureTech Ltd., H1 2014 198
Pancreatic Cancer - Pipeline by Genelux Corporation, H1 2014 199
Pancreatic Cancer - Pipeline by GlycoMimetics, Inc., H1 2014 200
Pancreatic Cancer - Pipeline by Biothera, Inc., H1 2014 201
Pancreatic Cancer - Pipeline by Medisyn Technologies, Inc., H1 2014 202
Pancreatic Cancer - Pipeline by Keystone Nano, Inc., H1 2014 203
Pancreatic Cancer - Pipeline by Pique Therapeutics, H1 2014 204
Pancreatic Cancer - Pipeline by Arch Biopartners, Inc., H1 2014 205
Pancreatic Cancer - Pipeline by Clovis Oncology, Inc., H1 2014 206
Pancreatic Cancer - Pipeline by 3-V Biosciences, Inc., H1 2014 207
Pancreatic Cancer - Pipeline by PharmAbcine, Inc., H1 2014 208
Pancreatic Cancer - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2014 209
Pancreatic Cancer - Pipeline by Sunshine Biopharma, Inc., H1 2014 210
Pancreatic Cancer - Pipeline by NuCana BioMed Limited, H1 2014 211
Pancreatic Cancer - Pipeline by KAEL-GemVax Co., Ltd., H1 2014 212
Pancreatic Cancer - Pipeline by Nuvilex, Inc., H1 2014 213
Pancreatic Cancer - Pipeline by iCeutica, Inc., H1 2014 214
Pancreatic Cancer - Pipeline by Incuron, LLC, H1 2014 215
Pancreatic Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 216
Pancreatic Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2014 217
Pancreatic Cancer - Pipeline by Polaris Group, H1 2014 218
Pancreatic Cancer - Pipeline by BiOrion Technologies B.V., H1 2014 219
Pancreatic Cancer - Pipeline by DEKK-TEC, Inc., H1 2014 220
Pancreatic Cancer - Pipeline by IkerChem S.L., H1 2014 221
Pancreatic Cancer - Pipeline by Regulon Inc., H1 2014 222
Pancreatic Cancer - Pipeline by TAU Therapeutics, LLC, H1 2014 223
Pancreatic Cancer - Pipeline by Gradalis Inc., H1 2014 224
Pancreatic Cancer - Pipeline by CytoVac A/S, H1 2014 225
Pancreatic Cancer - Pipeline by SignPath Pharma Inc, H1 2014 226
Pancreatic Cancer - Pipeline by BerGenBio AS, H1 2014 227
Pancreatic Cancer - Pipeline by CytomX Therapeutics, Inc., H1 2014 228
Pancreatic Cancer - Pipeline by Intezyne, Inc, H1 2014 229
Pancreatic Cancer - Pipeline by Sialix, Inc., H1 2014 230
Pancreatic Cancer - Pipeline by Igenica, Inc., H1 2014 231
Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals, LLC., H1 2014 232
Pancreatic Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 233
Pancreatic Cancer - Pipeline by Apexigen, Inc., H1 2014 234
Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H1 2014 235
Pancreatic Cancer - Pipeline by Kadmon Pharmaceuticals, LLC, H1 2014 236
Pancreatic Cancer - Pipeline by centrose llc, H1 2014 237
Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd., H1 2014 238
Pancreatic Cancer - Pipeline by NeoPharm Co., Ltd., H1 2014 239
Pancreatic Cancer - Pipeline by CureFAKtor Pharmaceuticals. LLC, H1 2014 240
Pancreatic Cancer - Pipeline by Kancera AB, H1 2014 241
Pancreatic Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H1 2014 242
Pancreatic Cancer - Pipeline by Vaxeal Holding SA, H1 2014 243
Pancreatic Cancer - Pipeline by Pharma Two B Ltd, H1 2014 244
Pancreatic Cancer - Pipeline by Valens Therapeutics, Inc., H1 2014 245
Pancreatic Cancer - Pipeline by Qu Biologics Inc., H1 2014 246
Pancreatic Cancer - Pipeline by CZ BioMed Corp, H1 2014 247
Pancreatic Cancer - Pipeline by IMPACT Therapeutics, Inc., H1 2014 248
Pancreatic Cancer - Pipeline by LivTech, Inc., H1 2014 249
Pancreatic Cancer - Pipeline by Io Therapeutics, Inc., H1 2014 250
Pancreatic Cancer - Pipeline by Bioncotech Therapeutics S.L., H1 2014 251
Pancreatic Cancer - Pipeline by Tactic Pharma, LLC, H1 2014 252
Pancreatic Cancer - Pipeline by Immune Pharmaceuticals, Inc., H1 2014 253
Pancreatic Cancer - Pipeline by Targovax AS, H1 2014 254
Pancreatic Cancer - Pipeline by InvivoGen Therapeutics, H1 2014 255
Pancreatic Cancer - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 256
Pancreatic Cancer - Pipeline by StemPar Sciences, Inc., H1 2014 257
Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H1 2014 258
Pancreatic Cancer - Pipeline by Oncomatrix, S.L., H1 2014 259
Pancreatic Cancer - Pipeline by Argon Pharma S.L., H1 2014 260
Pancreatic Cancer - Pipeline by cCAM Biotherapeutics Ltd., H1 2014 261
Pancreatic Cancer - Pipeline by Ability Pharma, SL, H1 2014 262
Pancreatic Cancer - Pipeline by Pharmedartis GmbH, H1 2014 263
Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H1 2014 264
Pancreatic Cancer - Pipeline by Oncology Research International Limited, H1 2014 265
Pancreatic Cancer - Pipeline by MediaPharma s.r.l., H1 2014 266
Pancreatic Cancer - Pipeline by TARGETOME, H1 2014 267
Pancreatic Cancer - Pipeline by Huabo Biopharm Co., Ltd., H1 2014 268
Assessment by Monotherapy Products, H1 2014 269
Assessment by Combination Products, H1 2014 270
Number of Products by Stage and Target, H1 2014 273
Number of Products by Stage and Mechanism of Action, H1 2014 284
Number of Products by Stage and Route of Administration, H1 2014 295
Number of Products by Stage and Molecule Type, H1 2014 298
Pancreatic Cancer Therapeutics - Recent Pipeline Updates, H1 2014 754
Pancreatic Cancer - Dormant Projects, H1 2014 934
Pancreatic Cancer - Dormant Projects (Contd..1), H1 2014 935
Pancreatic Cancer - Dormant Projects (Contd..2), H1 2014 936
Pancreatic Cancer - Dormant Projects (Contd..3), H1 2014 937
Pancreatic Cancer - Dormant Projects (Contd..4), H1 2014 938
Pancreatic Cancer - Dormant Projects (Contd..5), H1 2014 939
Pancreatic Cancer - Dormant Projects (Contd..6), H1 2014 940
Pancreatic Cancer - Dormant Projects (Contd..7), H1 2014 941
Pancreatic Cancer - Dormant Projects (Contd..8), H1 2014 942
Pancreatic Cancer - Dormant Projects (Contd..9), H1 2014 943
Pancreatic Cancer - Dormant Projects (Contd..10), H1 2014 944
Pancreatic Cancer - Dormant Projects (Contd..11), H1 2014 945
Pancreatic Cancer - Discontinued Products, H1 2014 946
List of Figures
Number of Products under Development for Pancreatic Cancer, H1 2014 46
Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H1 2014 47
Number of Products under Development by Companies, H1 2014 48
Number of Products under Investigation by Universities/Institutes, H1 2014 64
Comparative Analysis by Clinical Stage Development, H1 2014 69
Comparative Analysis by Clinical Stage Development, H1 2014 70
Comparative Analysis by Early Stage Products, H1 2014 71
Assessment by Monotherapy Products, H1 2014 269
Assessment by Combination Products, H1 2014 270
Number of Products by Top 10 Target, H1 2014 271
Number of Products by Stage and Top 10 Target, H1 2014 272
Number of Products by Top 10 Mechanism of Action, H1 2014 282
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 283
Number of Products by Top 10 Route of Administration, H1 2014 293
Number of Products by Stage and Top 10 Route of Administration, H1 2014 294
Number of Products by Top 10 Molecule Type, H1 2014 296
Number of Products by Stage and Top 10 Molecule Type, H1 2014 297
